Twist Bioscience’s Lobbying Spend: The Silent Signal in Synthetic Biology’s Regulatory Chess Game
Kraken’s Options Gambit: The Derivatives Play That Could Make or Break Its IPO
China’s Commercial BCI Launch Steals Neuralink’s ‘First’—Now the Race Is a Two-Horse Sprint
Twelve’s CO2-to-jet-fuel pathway just reset the carbon math for aviation